1. The Effect of Lebrikizumab on Inflammatory Biomarkers in Patients with Asthma.
- Author
-
Szefler, Stanley J., Corren, Jonathan, Silverberg, Jonathan, Okragly, Angela, Zhe Sun, Natalie, Chitra R., Zitnik, Ralph, Siu, Kimberly, and Blauvelt, Andrew
- Subjects
ASTHMATICS ,BIOMARKERS ,T helper cells - Abstract
Expert Interview Asthma Keywords: Keywords: Asthma; biologics; biomarkers; humanized monoclonal antibody; interleukin-13; lebrikizumab EN Asthma biologics biomarkers humanized monoclonal antibody interleukin-13 lebrikizumab Asthma is a heterogeneous disease with notable variationin its clinical course and response to treatment. It will be important todetermine the differences in response to the various asthma biologicsamong patients with severe asthma to develop a precision medicineapproach to management. Figure 1: Asthma biomarker level results from theLAVOLTA I study that assessed the use oflebrikizumab in patients with severe asthma Figure provided by Roche (Basel, Switzerland). [Extracted from the article]
- Published
- 2023
- Full Text
- View/download PDF